Trio, Ajinomoto to develop cancer therapeutic

By The Science Advisory Board staff writers

May 1, 2020 -- Cancer therapeutics company Trio Pharmaceuticals and biopharmaceutical contract development and manufacturing company Ajinomoto Bio-Pharma Services have announced a partnership to develop cancer therapeutics.

Through the partnership, Ajinomoto Bio-Pharma will use its AJICAP site-specific technology to conjugate a cytotoxic payload to Trio's lead oncology candidate. Trio will then evaluate the functionality of the Triobody Drug Conjugate (TDC), an antibody-drug conjugation that targets tumor growth and immunosuppression.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.